Complete List of Approved and Investigational GLP‑1 Drugs – July 2025

Glucagon-like peptide-1 receptor agonists (GLP‑1 RAs) are a growing class of medications used to manage type 2 diabetes and obesity. Here’s a comprehensive overview of all currently approved and investigational GLP‑1 drugs as of 2025.

Approved GLP‑1 Receptor Agonists

Semaglutide

• Brand Names: Ozempic, Rybelsus, Wegovy
• Approval: FDA (USA), EMA (Europe), TGA (Australia), PMDA (Japan)
• Indications: Type 2 diabetes, weight management (obesity)
• Learn more about semaglutide

Tirzepatide

• Brand Name: Mounjaro (FDA), Zepbound (obesity)
• Approval: USA, pending in EU and other countries
• Mechanism: Dual GIP/GLP-1 agonist
• Full profile on tirzepatide

Liraglutide

• Brand Names: Victoza, Saxenda
• Approval: Global
• Indications: Type 2 diabetes, obesity (Saxenda)
• See liraglutide uses and data

Dulaglutide

• Brand Name: Trulicity
• Approval: Global
• Dosing: Weekly injection
• Explore dulaglutide

Exenatide

• Brand Names: Byetta (daily), Bydureon (weekly – discontinued in some regions)
• Approval: Varies by region
• Learn more about exenatide

Lixisenatide

• Brand Name: Adlyxin
• Approval: Limited; more common in Europe
• Combo Drug: iGlarLixi (with insulin glargine)

Combination GLP‑1 Products

• Suliqua: Lixisenatide + Insulin Glargine
• Soliqua (US): Same as Suliqua
• Xultophy: Liraglutide + Insulin Degludec

Investigational or Pipeline GLP‑1 Drugs (as of 2025)

• Retatrutide (Eli Lilly): Triple agonist (GIP, GLP‑1, Glucagon); in Phase 3 trials
• Danuglipron (Pfizer): Oral GLP‑1 in development
• Orforglipron (Lilly): Non-peptide oral GLP‑1; Phase 3
• Efinopegdutide (Merck): Long-acting GLP‑1 RA; investigational
• CagriSema (Novo Nordisk): Cagrilintide + Semaglutide combo for weight loss

Discontinued or Market Withdrawn GLP‑1 Agonists

• Bydureon: Extended-release exenatide; withdrawn in U.S. in 2024
• Albiglutide (Tanzeum): Withdrawn in 2018 for commercial reasons

Final Thoughts

The GLP‑1 landscape is expanding rapidly, with several promising drugs in the pipeline. As research continues and new products emerge, patient access and therapeutic options will continue to evolve.